On June 15, 2026, Edesa Biotech, Inc. (“Edesa Biotech”), a Canadian clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, completed a US$3.5 million private placement of common shares, pursuant to securities purchase agreement for a private investment in public equity (“PIPE”) transaction under the rules of the Nasdaq Stock Market.
The PIPE was led by Edesa Biotech’s CEO, Dr. Pardeep Nijhawan and additional healthcare focused investors. Edesa Biotech plans to use the net proceeds from the PIPE to fund the continued advancement of the Company’s vitiligo program, the Company’s drug candidate, paridiprubart, and for working capital and general corporate purposes.
Fasken advised Edesa Biotech on the Canadian law aspects of the transaction with a team comprised of Justine Connors, Wojtek Baraniak, Myroslav Chwaluk, Sam Li, and Barbara Clark.
Jurisdiction
- Ontario
